|Dr. Helen I. Torley||Pres, CEO & Director||1.25M||N/A||1963|
|Ms. Laurie D. Stelzer||Sr. VP & CFO||650.64k||N/A||1968|
|Mr. Harry J. Leonhardt||Sr. VP, Gen. Counsel, Chief Compliance Officer & Corp. Sec.||619.76k||N/A||1957|
|Mr. Mark J. Gergen||Former Chief Operating Officer||222.53k||N/A||1963|
|Dr. Michael J. LaBarre Ph.D.||Chief Scientific Officer and VP||N/A||N/A||1964|
Halozyme Therapeutics, Inc., a biotechnology company, researches, develops, and commercializes human enzymes and other drug candidates in the United States, Switzerland, and internationally. The company's human enzymes are used to facilitate the delivery of injected drugs and fluids, enhancing the efficacy and the convenience of other drugs or can be used to alter tissue structures for clinical benefit. Its products are based on the Enhanze technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. The company's pipeline include Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous fluid administration for achieving hydration; to enhance the dispersion and absorption of other injected drugs; in subcutaneous urography; and to enhance resorption of radiopaque agents. It also develops PEGylated recombinant human hyaluronidase for the treatment of pancreatic ductal adenocarcinoma, non-small cell lung cancer, gastric cancer, metastatic breast cancer, and cholangiocarcinoma and gall bladder cancer. In addition, the company develops PEGylated adenosine deaminase 2, an immune checkpoint inhibitor that targets adenosine. It has collaborations with F. Hoffmann-La Roche, Ltd.; Hoffmann-La Roche, Inc.; Baxalta US Inc.; Baxalta GmbH; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; Bristol-Myers Squibb Company; and Alexion Pharma Holding. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.
Halozyme Therapeutics, Inc.’s ISS Governance QualityScore as of July 1, 2018 is 2. The pillar scores are Audit: 2; Board: 1; Shareholder Rights: 4; Compensation: 4.